Washed Microbiota Transplantation for Eczema: Experimental Evidence and Safety Limits

Research-focused microbiome review; not a treatment recommendation.

An experimental gut–skin approach

A 2026 study evaluated washed microbiota transplantation in atopic dermatitis, measuring SCORAD, EASI, itch, quality of life and microbial profiles. The intervention is a processed microbiota procedure performed under clinical protocols—not a dietary supplement.

Why improvement would not prove mechanism

Symptoms can change over time, and participants may receive background skin care. Without rigorous randomization, blinding and an appropriate sham control, placebo effects and regression to the mean are difficult to separate. Even if gut and skin communities shift alongside EASI, temporal correlation does not establish that microbial rebalancing caused the response.

Procedure risks are substantial

Microbiota transplantation can transmit infectious organisms or antimicrobial-resistance genes despite donor screening. Processing standards, donor selection, route of administration and regulatory oversight matter. Adverse events may be gastrointestinal or systemic and can be serious in vulnerable patients.

Do not attempt this independently

Home fecal transplantation is unsafe. People should not purchase unregulated products or use another person’s biological material. This is especially dangerous for infants, pregnant people, older adults and anyone immunocompromised. Research participation should occur only through appropriately reviewed clinical studies.

What stronger evidence would require

Future work needs adequately powered randomized sham-controlled trials, standardized manufacturing, long safety follow-up, transparent adverse-event reporting and replication. Clinical benefit should be judged separately from sequencing endpoints.

Bottom line

The study is scientifically interesting but does not make microbiota transplantation a standard eczema treatment. Safety and causal efficacy remain unresolved.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Washed microbiota transplantation study
2. Systemic therapies and skin bacteriome pilot
3. Abrocitinib and the skin microbiome study
4. Oral microbiome with dupilumab or upadacitinib
5. Topical Lactobacillus lactis pilot trial
6. Qing-Re-Qu-Shi multi-omics randomized trial
7. Nature-based microbial exposure pilot
8. Child dupilumab skin and gut microbiome pilot
9. Pediatric skin-microbiome emollient trial
10. Pediatric gut and skin microbiota case-control study
11. XZ.700 endolysin randomized trial
12. Staphylococcus hominis A9 safety trial
13. B244 itch randomized trial
14. Farnesol moisturizer microbiome study
15. AAD topical therapy guideline
16. AAD systemic therapy guideline
17. AAAAI/ACAAI GRADE guideline
18. Atopic dermatitis microbiome review
19. Staphylococcus aureus and atopic dermatitis review
20. Skin microbiome in atopic dermatitis review
21. Dupilumab SOLO phase 3 trials
22. Upadacitinib Measure Up trials
23. Abrocitinib JADE MONO-1 trial
24. HOME core outcome set

Referenced researchers do not endorse Dr. Arsy products.